Hariprasad Vankayalapati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5018064/publications.pdf

Version: 2024-02-01

61 papers	2,258 citations	411340 20 h-index	274796 44 g-index
66 all docs	66 docs citations	66 times ranked	3942 citing authors

#	Article	IF	Citations
1	SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. Journal of Clinical Investigation, 2022, 132, .	3.9	17
2	A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers, 2021, 13, 446.	1.7	10
3	The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin Î²-Like 1-Î²-Catenin Protein Complex. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 77-86.	1.3	5
4	A computational study of structural differences of binding of NADP+ and G6P substrates to G6PD Mediterraneanc.563T, G6PD Aâ^'c.202A/c.376G, G6PD Cairoc.404C and G6PD Gazac.536A mutations. Blood Cells, Molecules, and Diseases, 2021, 89, 102572.	0.6	5
5	The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS ONE, 2020, 15, e0235705.	1.1	44
6	Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents. Molecules, 2020, 25, 645.	1.7	9
7	Abstract P3-10-01: Development and characterization of a first-in-class small molecule inhibitor of PELP1. , 2020, , .		0
8	Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription Factors. SLAS Discovery, 2019, 24, 77-85.	1.4	2
9	Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT). , 2019, , .		1
10	Abstract 324: SIK2 inhibitors regulate DNA repair pathway and sensitize ovarian cancer to PARP1 inhibitors. , 2018, , .		1
11	Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo -Î²- N -acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2962-2966.	1.0	39
12	-indazol derivatives as potent PDK1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5473-5480.	1.0	12
13	Ruthenium(II)- and copper(I)-catalyzed synthesis of click-xylosides and assessment of their glycosaminoglycan priming activity. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5027-5030.	1.0	3
14	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clinical Cancer Research, 2017, 23, 1945-1954.	3.2	54
15	Abstract LB-296: Discovery of ARN-3261 as a potent, selective, orally available SIK2 inhibitor for treating ovarian, endometrial, primary peritoneal, fallopian tube, and triple negative breast cancers. Cancer Research, 2017, 77, LB-296-LB-296.	0.4	2
16	SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival. Molecular and Cellular Biology, 2016, 36, 3048-3057.	1.1	22
17	Abstract 3032: A novel compound ARN-3236 inhibits SIK2 and sensitizes ovarian cancer to paclitaxel. Cancer Research, 2016, 76, 3032-3032.	0.4	1
18	Abstract 1123: The role of proto-oncogene PELP1 in breast cancer stem cell maintenance and therapy resistance. , 2016, , .		0

#	Article	IF	Citations
19	Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime Î²-Catenin Pathway Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 5854-5862.	2.9	17
20	Inhibition of Nek2 by Small Molecules Affects Proteasome Activity. BioMed Research International, 2014, 2014, 1-13.	0.9	19
21	Abstract 749: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts. , 2014, , .		1
22	A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Journal of Molecular Medicine, 2013, 91, 507-512.	1.7	155
23	Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents. ACS Medicinal Chemistry Letters, 2013, 4, 1142-1147.	1.3	13
24	High-Throughput Virtual Screening Identifies Novel Nâ€²-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 9496-9508.	2.9	173
25	Use of a Bacteriophage Lysin to Identify a Novel Target for Antimicrobial Development. PLoS ONE, 2013, 8, e60754.	1.1	41
26	Chemical Genetic Screen Reveals a Role for Desmosomal Adhesion in Mammary Branching Morphogenesis. Journal of Biological Chemistry, 2013, 288, 2261-2270.	1.6	19
27	Abstract 5543: Inhibition of the tyrosine kinase receptor Axl blocks cell invasion and promotes apoptosis in pancreatic cancer cells.. , 2013, , .		1
28	Abstract 3391: Overexpression of Nek2 promotes bortezomib resistance in multiple myeloma cells.. , 2013, , .		0
29	Abstract 4413: Mechanisms of sensitivity to treatment with the PDK1 inhibitors HCI-1680 and HCI-1708.. , 2013, , .		0
30	Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Gaza Strip Palestinians. Blood Cells, Molecules, and Diseases, 2012, 49, 152-158.	0.6	17
31	Abstract 2776: Inhibition of Nek2 by novel small molecules affects proteasome activity. , 2012, , .		0
32	Targeting Axl and Mer Kinases in Cancer. Molecular Cancer Therapeutics, 2011, 10, 1763-1773.	1.9	202
33	Structureâ€“Activity Analysis and Cell-Based Optimization of Human Galactokinase Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 667-672.	1.3	19
34	Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 907-912.	1.3	72
35	In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Experimental Hematology, 2011, 39, 14-25.	0.2	6
36	Abstract 2577: Targeting the Axl tyrosine kinase receptor in pancreatic cancer. , 2011, , .		0

#	Article	IF	Citations
37	Abstract 2788: Design, optimization, and biological evaluation of potent irreversible inhibitors of BTK kinase. , 2011, , .		0
38	Abstract 3609: Homology structure-based design, synthesis and biological evaluation of a series of novel Axl and Mer kinase inhibitors. , 2011, , .		0
39	Abstract 1368: Fragment-based design, synthesis and biological evaluation of a series of novel PDK1 inhibitors. , 2011, , .		0
40	S110, a 5-Aza-2â€²-Deoxycytidineâ€“Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth. Molecular Cancer Therapeutics, 2010, 9, 1443-1450.	1.9	142
41	Abstract C206:In vivoactivity of SGIâ€1252, a potent, smallâ€molecule dual inhibitor of JAK2 and ALK2. , 2009, , .		2
42	Targeting Axl Kinase in Hematological Malignancies.. Blood, 2009, 114, 2758-2758.	0.6	1
43	Abstract C199: Development of potent, smallâ€molecule inhibitors of ETK. , 2009, , .		0
44	Abstract B263: Mechanistic, functional, andin vivo efficacy of inhibiting ETK/BMX in cancer models. , 2009, , .		0
45	Targeting the JAK2 Kinase in Hematological Malignancies.. Blood, 2007, 110, 3560-3560.	0.6	0
46	Targeting Pim Kinases in Hematological Malignancies.. Blood, 2007, 110, 2655-2655.	0.6	1
47	Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Molecular Cancer Therapeutics, 2006, 5, 1764-1773.	1.9	79
48	Determination of the importance of the stereochemistry of psorospermin in topoisomerase IIâ€“induced alkylation of DNA and in vitro and in vivo biological activity. Molecular Cancer Therapeutics, 2005, 4, 1729-1739.	1.9	20
49	Design and Synthesis of an Expanded Porphyrin That Has Selectivity for the c-MYC G-Quadruplex Structure. Journal of the American Chemical Society, 2005, 127, 2944-2959.	6.6	303
50	Conformationally Restricted Analogues of Psorospermin:Â Design, Synthesis, and Bioactivity of Natural-Product-Related Bisfuranoxanthones. Journal of Medicinal Chemistry, 2005, 48, 2993-3004.	2.9	35
51	Structure of a Quinobenzoxazineâ”G-Quadruplex Complex by REDOR NMR. Biochemistry, 2004, 43, 11953-11958.	1.2	28
52	Design, Synthesis, and Evaluation of Psorospermin/Quinobenzoxazine Hybrids as Structurally Novel Antitumor Agents. Journal of Medicinal Chemistry, 2003, 46, 2958-2972.	2.9	35
53	Structure-Based Design of Novel Anti-Cancer Agents TargetingAurora Kinases. Anti-Cancer Agents in Medicinal Chemistry, 2003, 3, 25-34.	7.0	22
54	Telomestatin, a Potent Telomerase Inhibitor That Interacts Quite Specifically with the Human Telomeric Intramolecular G-Quadruplex. Journal of the American Chemical Society, 2002, 124, 2098-2099.	6.6	494

#	Article	IF	Citations
55	Stereoselective O-glycosylation reactions using glycosyl donors with diphenylphosphinate and propane-1,3-diyl phosphate leaving groups. Tetrahedron: Asymmetry, 2001, 12, 1373-1381.	1.8	25
56	Efficient stereocontrolled synthesis of C-glycosides using glycosyl donors substituted by propane 1,3-diyl phosphate as the leaving group. Tetrahedron: Asymmetry, 2001, 12, 1727-1735.	1.8	17
57	A new glycosylation strategy for the synthesis of mannopyranosides. Tetrahedron: Asymmetry, 2000, 11, 125-138.	1.8	26
58	A simple polar deacetylated caloporoside derivative is a positive modulator of the GABAA chloride channel complex in cortical mammalian neurones. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1759-1761.	1.0	5
59	Synthesis of a novel oxoxanthenoisoquinoline via a palladium-catalysed cross-coupling reaction; as a fluorophore. Tetrahedron Letters, 2000, 41, 2987-2990.	0.7	7
60	Stereoselective synthesis of Î±-L-Fucp-(1,2)- and -(1,3)-Î²-D-Galp(1)-4-methylumbelliferone using glycosyl donor substituted by propane-1,3-diyl phosphate as leaving group. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 2187-2193.	1.3	13
61	Synthesis of fucosidase substrates using propane-1,3-diyl phosphate as the anomeric leaving group. Tetrahedron Letters, 1999, 40, 3925-3928.	0.7	19